donepezil has been researched along with Down Syndrome in 31 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of our study was to assess the efficacy and safety of donepezil in young adults with Down syndrome (DS) but no evidence of Alzheimer disease (AD)." | 9.14 | The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. ( Capone, GT; Handen, BL; Heller, JH; Kishnani, PS; McRae, T; Richardson, S; Seltzer, B; Sommer, BR; Spiridigliozzi, GA, 2009) |
| "The objective of this 10-week, randomized, double-blind, placebo-controlled multicenter study was to assess the efficacy and safety of donepezil for the treatment of cognitive dysfunction exhibited by children with Down syndrome (DS)." | 9.14 | Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. ( Escobar, L; Heller, JH; Kishnani, PS; Lott, I; McRae, T; Richardson, S; Spiridigliozzi, GA; Zhang, R, 2010) |
| "To determine whether individuals with Down syndrome and Alzheimer disease will show improvement after institution of donepezil treatment." | 9.10 | Down syndrome and Alzheimer disease: response to donepezil. ( Doran, E; Lott, IT; Nelson, L; Osann, K, 2002) |
| "Our goal in this study was to determine whether donepezil, an acetylcholinesterase inhibitor, would improve cognitive functioning in 19 subjects with Down syndrome and no dementia." | 9.10 | Effects of donepezil on cognitive functioning in Down syndrome. ( Chicoine, B; Chong, G; Fahey, C; Gitelman, D; Johnson, N, 2003) |
| " A 38-year-old woman with Down syndrome, diagnosed with secondary progressive dementia when her mental state had deteriorated rapidly after graduation from junior high school, started donepezil treatment." | 7.73 | Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil. ( Aikawa, K; Amamoto, N; Aoki, M; Doi, T; Hamada, H; Harada, J; Kondoh, T; Moriuchi, H; Nakashima, M; Ogawa, Y; Sasaki, H; Tanaka, T, 2005) |
| "Donepezil was dosed once daily at 2." | 6.73 | Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series. ( Crissman, BG; Dawson, D; Eells, R; Heller, JH; Kishnani, PS; Li, J; Spiridigliozzi, GA; Sullivan-Saarela, JA, 2007) |
| "The management of dementia in Alzheimer's disease has dramatically changed since the development of anti-dementia drugs." | 6.42 | Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. ( Prasher, VP, 2004) |
| "The objective of our study was to assess the efficacy and safety of donepezil in young adults with Down syndrome (DS) but no evidence of Alzheimer disease (AD)." | 5.14 | The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. ( Capone, GT; Handen, BL; Heller, JH; Kishnani, PS; McRae, T; Richardson, S; Seltzer, B; Sommer, BR; Spiridigliozzi, GA, 2009) |
| "The objective of this 10-week, randomized, double-blind, placebo-controlled multicenter study was to assess the efficacy and safety of donepezil for the treatment of cognitive dysfunction exhibited by children with Down syndrome (DS)." | 5.14 | Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. ( Escobar, L; Heller, JH; Kishnani, PS; Lott, I; McRae, T; Richardson, S; Spiridigliozzi, GA; Zhang, R, 2010) |
| "To determine whether individuals with Down syndrome and Alzheimer disease will show improvement after institution of donepezil treatment." | 5.10 | Down syndrome and Alzheimer disease: response to donepezil. ( Doran, E; Lott, IT; Nelson, L; Osann, K, 2002) |
| "Our goal in this study was to determine whether donepezil, an acetylcholinesterase inhibitor, would improve cognitive functioning in 19 subjects with Down syndrome and no dementia." | 5.10 | Effects of donepezil on cognitive functioning in Down syndrome. ( Chicoine, B; Chong, G; Fahey, C; Gitelman, D; Johnson, N, 2003) |
| "This review discusses the laboratory and clinical research supporting the rationale for the efficacy of donepezil (Aricept USA) in enhancing cognition in autism, Alzheimer disease, Down syndrome, traumatic brain injury, Attention Deficit Hyperactivity Disorder (ADHD), and schizophrenia." | 4.84 | Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature. ( Valdovinos, MG; Williams, DC; Yoo, JH, 2007) |
| " A 38-year-old woman with Down syndrome, diagnosed with secondary progressive dementia when her mental state had deteriorated rapidly after graduation from junior high school, started donepezil treatment." | 3.73 | Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil. ( Aikawa, K; Amamoto, N; Aoki, M; Doi, T; Hamada, H; Harada, J; Kondoh, T; Moriuchi, H; Nakashima, M; Ogawa, Y; Sasaki, H; Tanaka, T, 2005) |
| "Studies on potential treatments for dementia in this population are still scarce." | 2.82 | Pharmacological Approaches to the Treatment of Dementia in Down Syndrome: A Systematic Review of Randomized Clinical Studies. ( de Oliveira, LC; de Paula Faria, D, 2022) |
| "Donepezil was dosed once daily at 2." | 2.73 | Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series. ( Crissman, BG; Dawson, D; Eells, R; Heller, JH; Kishnani, PS; Li, J; Spiridigliozzi, GA; Sullivan-Saarela, JA, 2007) |
| "People with Down syndrome are vulnerable to developing dementia at an earlier age than the general population." | 2.52 | Pharmacological interventions for cognitive decline in people with Down syndrome. ( Hanratty, J; Livingstone, N; Macdonald, G; McShane, R, 2015) |
| "Whereas Trisomy 21 is one of the most widespread genetic causes of intellectual disability (ID), it still is one of the least understood of all genetic ID syndromes." | 2.49 | Atypical aging in Down syndrome. ( Zigman, WB, 2013) |
| "Down syndrome is probably believed too special and therefore many clinicians seems to hesitate to attend them or scare to give wrong treatment." | 2.46 | [Care continuity for patients with Down syndrome during transition from childhood to adulthood]. ( Hasegawa, T, 2010) |
| "The management of dementia in Alzheimer's disease has dramatically changed since the development of anti-dementia drugs." | 2.42 | Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. ( Prasher, VP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.45) | 18.2507 |
| 2000's | 20 (64.52) | 29.6817 |
| 2010's | 8 (25.81) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| de Oliveira, LC | 1 |
| de Paula Faria, D | 1 |
| Zigman, WB | 1 |
| Tamasaki, A | 1 |
| Saito, Y | 1 |
| Ueda, R | 1 |
| Ohno, K | 1 |
| Yokoyama, K | 1 |
| Satake, T | 1 |
| Sakuma, H | 1 |
| Takahashi, Y | 1 |
| Kondoh, T | 4 |
| Maegaki, Y | 1 |
| Livingstone, N | 1 |
| Hanratty, J | 1 |
| McShane, R | 1 |
| Macdonald, G | 1 |
| Mohan, M | 1 |
| Carpenter, PK | 1 |
| Bennett, C | 1 |
| Kishnani, PS | 8 |
| Sommer, BR | 1 |
| Handen, BL | 1 |
| Seltzer, B | 1 |
| Capone, GT | 2 |
| Spiridigliozzi, GA | 8 |
| Heller, JH | 7 |
| Richardson, S | 2 |
| McRae, T | 2 |
| Hasegawa, T | 1 |
| Lott, I | 1 |
| Escobar, L | 1 |
| Zhang, R | 1 |
| Kanno, A | 1 |
| Itoh, H | 1 |
| Nakashima, M | 3 |
| Honda, R | 1 |
| Kojima, M | 1 |
| Noguchi, M | 1 |
| Nakane, H | 1 |
| Nozaki, H | 1 |
| Sasaki, H | 3 |
| Nagai, T | 1 |
| Kosaki, R | 1 |
| Kakee, N | 1 |
| Okuyama, T | 1 |
| Fukuda, M | 1 |
| Ikeda, M | 1 |
| Shibata, Y | 1 |
| Moriuchi, H | 3 |
| Whitney, KN | 1 |
| Wenger, GR | 1 |
| Lott, IT | 1 |
| Osann, K | 1 |
| Doran, E | 1 |
| Nelson, L | 1 |
| Sullivan, JA | 5 |
| Doraiswamy, PM | 4 |
| Krishnan, RR | 1 |
| Cipriani, G | 1 |
| Bianchetti, A | 1 |
| Trabucchi, M | 1 |
| Prasher, VP | 3 |
| Adams, C | 1 |
| Holder, R | 1 |
| Margallo-Lana, ML | 1 |
| Ballard, C | 1 |
| Morris, C | 1 |
| Kay, D | 1 |
| Tyrer, S | 1 |
| Moore, B | 1 |
| Johnson, N | 1 |
| Fahey, C | 1 |
| Chicoine, B | 1 |
| Chong, G | 1 |
| Gitelman, D | 1 |
| Crissman, BG | 3 |
| Amamoto, N | 1 |
| Doi, T | 1 |
| Hamada, H | 1 |
| Ogawa, Y | 1 |
| Aikawa, K | 1 |
| Tanaka, T | 1 |
| Aoki, M | 1 |
| Harada, J | 1 |
| Schill, D | 1 |
| Nardone, R | 1 |
| Marth, R | 1 |
| Ausserer, H | 1 |
| Bratti, A | 1 |
| Tezzon, F | 1 |
| Yoo, JH | 1 |
| Valdovinos, MG | 1 |
| Williams, DC | 1 |
| Sullivan-Saarela, JA | 1 |
| Eells, R | 1 |
| Dawson, D | 1 |
| Li, J | 1 |
| Rueda, N | 1 |
| Flórez, J | 1 |
| Martínez-Cué, C | 1 |
| Walter, BK | 1 |
| Krishnan, KR | 2 |
| Hemingway-Eltomey, JM | 1 |
| Lerner, AJ | 1 |
| Huxley, A | 1 |
| Haque, MS | 1 |
7 reviews available for donepezil and Down Syndrome
| Article | Year |
|---|---|
Pharmacological Approaches to the Treatment of Dementia in Down Syndrome: A Systematic Review of Randomized Clinical Studies.
Topics: Acetylcholinesterase; Cholinesterase Inhibitors; Dementia; Donepezil; Down Syndrome; Humans; Memanti | 2022 |
Atypical aging in Down syndrome.
Topics: Adult; Aging; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Dementia; Donepez | 2013 |
Pharmacological interventions for cognitive decline in people with Down syndrome.
Topics: Acetylcarnitine; Adult; Antioxidants; Cognition; Cognition Disorders; Donepezil; Down Syndrome; Huma | 2015 |
Donepezil for dementia in people with Down syndrome.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Humans; Indans; Piperidines; | 2009 |
[Care continuity for patients with Down syndrome during transition from childhood to adulthood].
Topics: Adolescent; Adult; Aged; Alzheimer Disease; Child; Comprehensive Health Care; Continuity of Patient | 2010 |
Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Galantamine; Hum | 2004 |
Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature.
Topics: Alzheimer Disease; Animals; Attention; Attention Deficit Disorder with Hyperactivity; Autistic Disor | 2007 |
12 trials available for donepezil and Down Syndrome
| Article | Year |
|---|---|
The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome.
Topics: Adult; Demography; Donepezil; Double-Blind Method; Down Syndrome; Female; Humans; Indans; Learning; | 2009 |
Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17.
Topics: Adolescent; Behavior; Caregivers; Child; Cholinesterase Inhibitors; Cognition Disorders; Diarrhea; D | 2010 |
Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double-blind, placebo-controlled trial.
Topics: Activities of Daily Living; Adult; Cognition Disorders; Donepezil; Double-Blind Method; Down Syndrom | 2011 |
Down syndrome and Alzheimer disease: response to donepezil.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Drug Administration Schedule | 2002 |
Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial.
Topics: Adult; Appetite; Cholinesterase Inhibitors; Diarrhea; Donepezil; Dose-Response Relationship, Drug; D | 2003 |
Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Down Syndrome; Humans; Indans; Lo | 2003 |
Effects of donepezil on cognitive functioning in Down syndrome.
Topics: Adolescent; Adult; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Dose-Response Relation | 2003 |
Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial.
Topics: Adolescent; Child; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Female; Humans; Indans; Lang | 2004 |
Pharmacokinetics of donepezil in Down syndrome.
Topics: Adolescent; Adult; Donepezil; Down Syndrome; Humans; Indans; Male; Nootropic Agents; Piperidines | 2005 |
Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series.
Topics: Adolescent; Child; Cholinesterase Inhibitors; Cognition; Donepezil; Down Syndrome; Drug Administrati | 2007 |
Cholinergic therapy for Down's syndrome.
Topics: Adaptation, Psychological; Adult; Cholinesterase Inhibitors; Dementia; Donepezil; Down Syndrome; Dru | 1999 |
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.
Topics: Adult; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Comorbidity; Donepezil; Double-Blind Meth | 2002 |
12 other studies available for donepezil and Down Syndrome
| Article | Year |
|---|---|
Effects of donepezil and serotonin reuptake inhibitor on acute regression during adolescence in Down syndrome.
Topics: Adolescent; Brain; Disease Progression; Donepezil; Down Syndrome; Electroencephalography; Humans; In | 2016 |
The emergence of pharmacotherapies for cognitive function in Down syndrome.
Topics: Adolescent; Child; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Donepezil; Dose-R | 2010 |
Working memory in the aged Ts65Dn mouse, a model for Down syndrome.
Topics: Aging; Animals; Antidepressive Agents; Central Nervous System Stimulants; Cognition; Conditioning, O | 2012 |
Donepezil use in the treatment of dementia associated with Down syndrome.
Topics: Adult; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Donepezil; Down Syndrome; Fema | 2003 |
Cognitive decline in Down syndrome.
Topics: Adult; Age Factors; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Down Syndro | 2003 |
Donepezil use in Down syndrome.
Topics: Adult; Cholinesterase Inhibitors; Dementia; Donepezil; Down Syndrome; Humans; Indans; Neuropsycholog | 2004 |
Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil.
Topics: Adult; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Down Syndrome; Female; H | 2005 |
[Dementia of trisomy 21. Improvement with donepezil].
Topics: Dementia; Donepezil; Down Syndrome; Humans; Indans; Nootropic Agents; Piperidines | 2005 |
Reduced short latency afferent inhibition in patients with Down syndrome and Alzheimer-type dementia.
Topics: Adult; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Female; Humans | 2006 |
Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome.
Topics: Acetylcholine; Animals; Brain; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Disease Mod | 2008 |
Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Comorbidity; Donepezil; Down Syndrome; Female; H | 1999 |
Donepezil for Down's syndrome.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Co | 2001 |